In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Questcor Pharmaceuticals, Inc.

http://www.questcor.com

Latest From Questcor Pharmaceuticals, Inc.

Pharma Execs Urge 'Balance' In China Payer Price Negotiations

The annual reimbursement price negotiations between pharma firms and China’s National Healthcare Security Administration are just around the corner. While some have chosen to walk away from the process completely, others including majors BeiGene and Hengrui are girding up for another round of potentially deep cuts.

China Pricing Strategies

A Tale Of Two Gene Therapy Biotechs: Freeline Divests As Kriya Invests

Freeline Therapeutics and Kriya are taking divergent paths to success amid market doldrums, as the former divests and pulls back on investment, while the latter bulks up its pipeline through an acquisition.

Companies Gene Therapy

FTC Steps Into FDA’s ‘Ministerial’ Gap, Seeks Delisting Of REMS Patent

Jazz’s REMS patent appears to cover only a method of distributing Xyrem not a method of using the drug and if so should be delisted from FDA’s Orange Book, FTC argues in Jazz infringement suit against Avadel, which had itself sued FDA seeking release from patent certification requirement.

Intellectual Property Legal Issues

FTC Steps Into FDA’s ‘Ministerial’ Gap, Seeks Delisting Of REMS Patent

Jazz’s REMS patent appears to cover only a method of distributing Xyrem not a method of using the drug and if so should be delisted from FDA’s Orange Book, FTC argues in Jazz infringement suit against Avadel, which had itself sued FDA seeking release from patent certification requirement.

Intellectual Property Legal Issues
See All

Company Information

  • Other Names / Subsidiaries
    • BioVectra Inc.
UsernamePublicRestriction

Register